Aptose Biosciences Advances TUSCANY Trial with Dose Escalation

The latest announcement is out from Aptose Biosciences ( (TSE:APS) ).

On August 6, 2025, Aptose Biosciences announced that the Cohort Safety Review Committee approved the escalation to a 160 mg dose of tuspetinib in their Phase 1/2 TUSCANY trial, following successful safety reviews of lower doses. The trial aims to develop a safe, mutation-agnostic frontline therapy for AML patients, with no dose-limiting toxicities reported in previous cohorts. Additionally, Aptose received a US$1.1M advance from Hanmi Pharmaceutical as part of an existing loan agreement, supporting the trial’s continuation and expansion.

The most recent analyst rating on (TSE:APS) stock is a Buy with a C$60.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on TSE:APS Stock

According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.

Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.

To see Spark’s full report on TSE:APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. Their lead product, tuspetinib (TUS), is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).

Average Trading Volume: 7,940

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$4.36M

See more data about APS stock on TipRanks’ Stock Analysis page.